Literature DB >> 24204025

miRNA dysregulation in breast cancer.

Laoighse Mulrane1, Sharon F McGee, William M Gallagher, Darran P O'Connor.   

Abstract

miRNAs have emerged, in the last decade, as key players in the carcinogenic process, with many candidates identified as playing important roles in many aspects of tumor development, growth, metastasis, and drug resistance. More recently, polymorphisms in miRNAs themselves or in their binding sites in target genes have been identified to incur increased risk of breast cancer in certain populations. In addition, epigenetic regulation and differential expression of processing enzymes has been shown to contribute to the aberrant expression of miRNAs in breast cancer. This review focuses on the area of miRNA dysregulation in breast cancer through both genetic and epigenetic mechanisms, and the impact of this dysregulation on breast cancer risk and resistance to therapies. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24204025     DOI: 10.1158/0008-5472.CAN-13-1841

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  Three-Dimensional Cellular Arrangement in Epithelial Ovarian Cancer Cell Lines TOV-21G and SKOV-3 is Associated with Apoptosis-Related miRNA Expression Modulation.

Authors:  Aline Brito de Lima; Luciana Maria Silva; Nikole Gontijo Gonçales; Maria Raquel Santos Carvalho; Agnaldo Lopes da Silva Filho; Letícia da Conceição Braga
Journal:  Cancer Microenviron       Date:  2018-01-06

Review 3.  Involvement of microRNAs in HER2 signaling and trastuzumab treatment.

Authors:  Ling Mao; Ai-Jun Sun; Jian-Zhong Wu; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2016-10-12

4.  Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.

Authors:  Hyang Sook Seol; Yoshimitsu Akiyama; Shu Shimada; Hee Jin Lee; Tae Im Kim; Sung Min Chun; Shree Ram Singh; Se Jin Jang
Journal:  Cancer Lett       Date:  2014-07-22       Impact factor: 8.679

5.  Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model.

Authors:  G Liang; Y Zhu; A Jing; J Wang; F Hu; W Feng; Z Xiao; B Chen
Journal:  Gene Ther       Date:  2016-08-02       Impact factor: 5.250

Review 6.  NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.

Authors:  Jonna Frasor; Lamiaa El-Shennawy; Joshua D Stender; Irida Kastrati
Journal:  Mol Cell Endocrinol       Date:  2014-10-18       Impact factor: 4.102

7.  Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients.

Authors:  Shu-wei Zhou; Bei-bei Su; Yong Zhou; Yue-qing Feng; Yu Guo; Yun-xiang Wang; Pan Qi; Sheng Xu
Journal:  Med Oncol       Date:  2014-10-01       Impact factor: 3.064

8.  Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.

Authors:  Shannon T Bailey; Thomas Westerling; Myles Brown
Journal:  Cancer Res       Date:  2014-11-11       Impact factor: 12.701

9.  miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  Xiaoyan Liu; Lei Bi; Qin Wang; Mingxin Wen; Ce Li; Yidan Ren; Qinlian Jiao; Jian-Hua Mao; Chuanxin Wang; Guangwei Wei; Yunshan Wang
Journal:  Oncogene       Date:  2018-03-20       Impact factor: 9.867

10.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.